Airfinity launches Vaccine Efficacy Meta-Analysis tool

Posted on Jul 9, 2021

Until now, there has been the lack of an up-to-date resource outlining efficacy and real-world effectiveness data for vaccines that are being rolled out globally. The rising need for such a tool has been accelerated further due to the rise of variants, which may significantly impact the protection from vaccines currently in use. Airfinity's new Vaccine Efficacy Meta-Analysis Tool aggregates and analyses all existing outcomes data to give an up-to-date assessment of a vaccine's effectiveness across different patient populations. Not only that but the tool also provides information about the impact of variants of concern and will update as and when new data is published.

This real-time tracking of vaccine effectiveness will allow governmental agencies to assess the impact of new variants of concern and risk to their populations and inform vaccine rollout strategies. Vaccine developers will be able to track the magnitude of protection imparted by their candidates or competitors and may use this data to inform alternative dosing regimens or further candidate development, if necessary.

Book a free walkthrough with our analysts and find out how the tool can benefit your team and strategic efforts.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022